POON Chiu Yee, Liona

POON Chiu Yee, Liona

Current Position:
Professor (Clinical)

Office Phone:
(852) 3505 1290

Email:
liona.poon@cuhk.edu.hk

 

Biographical details
Liona Poon was awarded MBBS from University of London in 2002 and undertook her specialty training in Obstetrics and Gynaecology in London. She gained a 3-year training fellowship from the Fetal Medicine Foundation and during this time, established a major screening programme for early detection of preeclampsia, which led to a Doctorate of Medicine (Research) in 2011. She then undertook subspecialty training in maternal fetal medicine at Imperial College Healthcare NHS Trust and King’s College Hospital NHS Foundation Trust with Mr TG Teoh and Professor KH Nicolaides as supervisors.

Qualifications:
MBBS (University of London), MRCOG, MD(Res) (University of London), Cert RCOG (Maternal and Fetal Medicine)

Research interests:
Her main research interests are in the prediction and prevention of maternal and perinatal morbidity and mortality. These include developing screening models for the prediction of aneuploidies, preeclampsia, fetal growth restriction, gestational diabetes, macrosomia, stillbirth, spontaneous preterm birth and induced labour. She is currently conducting a pan-European multicentre randomised controlled trial of Aspirin vs. placebo in the prevention of preterm preeclampsia (ASPRE), which is funded by the EC FP7 scheme. She has authored over 100 peer-reviewed publications in the top quartile of international journals in the field of Obstetrics and Gynaecology and Hypertension.

Grants:
EC FP7 (601852-2), NIHR EME (14/01/02), NIHR HTA (14/158), CUHK Start-up Support Fund, HK O&G Trust Fund

 

1FIGO (International Federation of Gynecology and Obstetrics) Postpregnancy Initiative: Long-term maternal implications of pregnancy complications-follow-up considerations.
Sheiner E, Kapur A, Retnakaran R, Hadar E, Poon LC, Mclntyre HD, Divakar H, Staff AC, Narula J, Kihara AB, Hod M.
Int J Gynaecol Obstet 2019 Sep;147:1-31
2Clinical evaluation of a first trimester pregnancy algorithm predicting the risk of small for gestational age neonates
Graham K, Park F, McLennan A, Pelosi M, Williams P, Poon LC, Hyett J
Aust N Z J Obstet Gynaecol. 2019 Oct;59(5):670-676
3Prenatal visualization of paraumbilical veins in fetus with intra-abdominal umbilical vein stricture and intrauterine growth restriction
Chan YM, Law KM, Poon LC, Leung TY
Ultrasound Obstet Gynecol. 2019 Nov;54(5):697-698
4Inter-manufacturer comparison of automated immunoassays for the measurement of soluble FMS-like tyrosine kinase-1 and placental growth factor
Cheng YKY, Poon LC, Shennan A, Leung TY, Sahota DS
Pregnancy Hypertens. 2019 Jul;17:165-171
5Maternal hemodynamics in screen-positive and screen-negative women of the ASPRE trial
Ling HZ, Guy GP, Bisquera A, Poon LC, Nicolaides KH, Kametas NA
Ultrasound Obstet Gynecol. 2019 Jul;54(1):51-57
6Reproductive outcomes after surgical treatment of asherman syndrome: A systematic review
Guo EJ, Chung JPW, Poon LC, Li TC
Best Pract Res Clin Obstet Gynaecol. 2019 Aug;59:98-114
7Transvaginal three-dimensional assessment of Sylvian fissures at 18-30 weeks’ gestation
Poon LC, Sahota DS, Chaemsaithong P, Nakamura T, Machida M, Naruse K, Wah YM, Leung TY, Pooh RK
Ultrasound Obstet Gynecol. 2019 Aug;54(2):190-198
8Increased Sylvian fissure angle as early sonographic sign of malformation of cortical development
Pooh RK, Machida M, Nakamura T, Uenishi K, Chiyo H, Itoh K, Yoshimatsu J, Ueda H, Ogo K, Chaemsaithong P, Poon LC
Ultrasound Obstet Gynecol. 2019 Aug;54(2):199-206
9Good clinical practice advice: First trimester screening and prevention of pre- eclampsia in singleton pregnancy FIGO Working Group on Good Clinical Practice in Maternal–Fetal Medicine
Poon LC
Int J Gynaecol Obstet. 2019 Mar;144(3):325-329
10Do specific ultrasonography features identified at the time of early pregnancy loss predict fetal chromosomal abnormality?  A systematic review and meta-analysis
Huang J, Zhu W, Tang J, Saravelos SH, Poon LC, Li TC
Genes Dis. 2019 Jun 6(2):129-137
11The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, McAuliffe F, Costa FD, von Dadelszen P, McIntyre HD, Kihara AB, Di Renzo GC, Romero R, D'Alton M, Berghella V, Nicolaides KH, Hod M, Hod M
Int J Gynaecol Obstet. 2019 May;145 Suppl 1:1-33
12Screening and prevention of pre-eclampsia: a review
Chaemsaithong P , Appiah EK , Sahota DS , Leung TY, Poon LC
Hong Kong J Gynaecol Obstet Midwifery 2019;19(1):56-72
13Factors that affect ultrasound-determined labor progress in women undergoing induction of labor
Chaemsaithong P, Kwan AHW, Tse WT, Lim WT, Chan WWY, Chong KC, Leung TY, Poon LC
Am J Obstet Gynecol. 2019 Jun;220(6):592.e1-592.e15
14Pre-induction transperineal ultrasound assessment for the prediction of labor outcome
Chan WWY, Chaemsaithong P, Lim WT, Tse WT, Kwan AHW, Leung TY, Sahota D, Poon LC
Fetal Diagn Ther. 2019 Apr;45(4):256-267
15Impact of preimplantation genetic testing for aneuploidy on obstetrical practice
Chan YM, Li TC, Poon LC
Curr Opin Obstet Gynecol. 2019 Apr;31(2):127-131
16Body mass index at 11–13 weeks’ gestation and pregnancy complications in a Southern Chinese population: a retrospective cohort study
Chaemsaithong P, Leung TY, Sahota DS, Cheng YKY, Leung WC, Lo TK, Poon LC
J Matern Fetal Neonatal Med. 2019 Jun;32(12):2056-2068
17Comment on "First Trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors"
Sahota DS, Poon LC
Prenat Diagn. 2018 Oct;38(11):891, 1 page
18Updates on Screening, Prevention, Treatment, and Genetic Markers for Preeclampsia
Palomaki GE, Martin JN Jr, Karumanchi SA, Poon LC
Clin Chem. 2018 Dec;64(12):1684-1689
19Objective assessment of the fetal facial profile at second and third trimester of pregnancy
Lu J, Sahota DS, Poon LC, Ting YH, Cheng YKY, Wang Y, Leung TY
Prenat Diagn. 2019 Jan;39(2):107-115
20The first-trimester of pregnancy - a window of opportunity for prediction and prevention of pregnancy complications and future life  
Poon LC, McIntyre HD, Hyett JA, da Fonseca EB, Hod M
Diabetes Res Clin Pract. 2018 Nov;145:20-30
21Maternal hemodynamics, fetal biometry and Doppler indices in pregnancies followed up for suspected fetal growth restriction
Roberts LA, Ling HZ, Poon LC, Nicolaides KH, Kametas NA
Ultrasound Obstet Gynecol. 2018 Oct;52(4):507-514
22Transverse technique: complementary approach to measurement of first-trimester uterine artery Doppler
Drouin O, Johnson J, Metcalfe A, Huber J, Schwarzenberger J,  Winters E, Stavness L, Chaemsaithong P, Tse AWT, Lu J, Lim WT, Leung TY, Bujold E, Sahota D, Poon LC
Ultrasound Obstet Gynecol. 2018 Nov;52(5):639-647
23Prediction of labor outcome using serial transperineal ultrasound in the first stage of labor
Chor CM, Poon LC, Leung TY
J Matern Fetal Neonatal Med. 2019 Jan;32(1):31-37
24Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE
Tan MY, Poon LC, Rolnik DL, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Greco E, Papaioannou G, Wright D, Nicolaides KH
Ultrasound Obstet Gynecol. 2018 Jul;52(1):52-59
25Uterine artery pulsatility index in the first trimester: assessment of intersonographer and intersampling site measurement differences
Chaemsaithong P, Ting YH, Cheng KYY, Poon LC, Leung TY, Sahota DS
J Matern Fetal Neonatal Med. 2018 Sep;31(17):2276-2283
26ASPRE trial: incidence of preterm pre-eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm
Poon LC, Rolnik DL, Tan MY, Delgado JL, Tsokaki T, Akolekar R, Singh M, Andrade W, Efeturk T, Jani JC, Plasencia W, Papaioannou G, Blazquez AR, Carbone IF, Wright D, Nicolaides KH
Ultrasound Obstet Gynecol. 2018 Jun;51(6):738-742
27Effect of change in posture on maternal functional hemodynamics at 35–37 weeks’ gestation
Guy GP, Ling HZ, Machuca M, Poon LC, Nicolaides KH
Ultrasound Obstet Gynecol. 2018 Mar;51(3):368-374
28Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia
Wright D, Poon LC, Rolnik DL, Syngelaki A, Delgado JL, Vojtassakova D, de Alvarado M, Kapeti E, Rehal A, Pazos A, Carbone IF, Dutemeyer V, Plasencia W, Papantoniou N, Nicolaides KH
Am J Obstet Gynecol. 2017 Dec;217(6):685.e1-685.e5
29Integrated Proteomic and Metabolomic prediction of Term Preeclampsia
Bahado-Singh R, Poon LC, Yilmaz A, Syngelaki A, Turkoglu O, Kumar P, Kirma J, Allos M, Accurti V, Li J, Zhao P, Graham SF, Cool DR, Nicolaides K
Sci Rep. 2017 Nov 23;7(1):16189 (Page 1-10)
30Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11-14 weeks: a randomized controlled study . E. Scazzocchio, D. Oros, D. Diaz, J. C. Ramirez, M. Ricart, E. Meler, R. González de Agüero, E. Gratacos and F. Figueras
Poon LC
Ultrasound Obstet Gynecol. 2017 Apr;49(4):433
31Protocol for measurement of mean arterial pressure at 10–40 weeks’ gestation
Roberts L, Chaemsaithong P, Sahota DS, Nicolaides KH, Poon LC
Pregnancy Hypertens. 2017 Oct;10:155-160
32Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history
Poon LC, Wright D, Rolnik DL, Syngelaki A, Delgado JL, Tsokaki T, Leipold G, Akolekar R, Shearing S, De Stefani L, Jani JC, Plasencia W, Evangelinakis N, Gonzalez-Vanegas O, Persico N, Nicolaides KH
Am J Obstet Gynecol. 2017 Nov;217(5):585.e1-585.e5
33ASPRE trial: performance of screening for preterm pre-eclampsia
Rolnik DL, Wright D, Poon LC, Syngelaki A, O'Gorman N, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Nicolaides KH
Ultrasound Obstet Gynecol 2017 Oct;50(4):492-495
34Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE).
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC
BMJ Open. 2016 Jun 28;6(6):e011801. doi: 10.1136/bmjopen-2016-011801.
35Protocol for the prospective validation study: 'Screening programme for pre-eclampsia' (SPREE)
Tan MY, Koutoulas L, Wright D, Nicolaides KH, Poon LC
Ultrasound Obstet Gynecol. 2017 Aug;50(2):175-179
36Metabolomic determination of pathogenesis of late-onset preeclampsia
Bahado-Singh RO, Syngelaki A, Mandal R, Graham SF, Akolekar R, Han B, Bjondahl TC, Dong E, Bauer S, Alpay-Savasan Z, Turkoglu O, Ogunyemi D, Poon LC, Wishart DS, Nicolaides KH
J Matern Fetal Neonatal Med. 2017 Mar;30(6):658-664
37Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH
N Engl J Med. 2017 Aug 17;377(7):613-622
38Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation
O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, Akolekar R, Cicero S, Janga D, Jani J, Molina F S, Paco Matallana C, Papantoniou N, Persico N, Plasencia W, Singh M, Nicolaides K H
Ultrasound Obstet Gynecol 2017 Jun;49(6):751-755
39Maternal cardiac function at 35-37 weeks' gestation: relationship with birth weight
Guy G.P., Ling H.Z., Machuca M., Poon LC, Nicolaides K.H.
Ultrasound Obstet Gynecol. 2017 Jan;49(1):67-72
40Maternal cardiac function at 35-37 weeks’ gestation: prediction of preeclampsia and gestational hypertension
Guy GP, Ling HZ, Garcia P, Poon LC, Nicolaides KH
Ultrasound in Obstetrics and Gynecology Jan 2017;49(1):61-66
41Maternal Cardiovascular Function at 35-37 Weeks' Gestation: Relation to Maternal Characteristics
Guy GP, Ling HZ, Garcia P, Poon LC, Nicolaides KH
Ultrasound in Obstetrics and Gynecology Jan 2017;49(1):39-45
42Birth weight in live births and stillbirths
Poon LC, Tan MY, Yerlikaya G, Syngelaki A, Nicolaides KH
Ultrasound Obstet Gynecol Nov 2016;48(5):602-606
43Metabolomic Determination of Pathogenesis of Late-onset Preeclampsia.
Bahado-Singh RO, Syngelaki A, Mandal R, Akolekar R, Han B, Bjondahl TC, Dong E, Bauer S, Alpay-Savasan Z, Graham S, Turkoglu O, Ogunyemi D, Poon LC, Wishart DS, Nicolaides KH.
Journal of Maternal Fetal and Neonatal Medicine 2016, J Matern Fetal Neonatal Med. 2016; 28: 1-7.
44Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE).
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC.
BMJ Open 2016; 6:e011801. doi: 10.1136/bmjopen-2016-011801.
45Risk of preterm birth following treatment for cervical disease: Stakeholder meeting summary.
Sasieni P, Castanon A, Landy R, Kyrgiou M, Kitchener H, Quigley M, Poon LC, Shennan A, Paraskevaidis E, Hollingworth A, Soutter P, Freeman Wang T, Peebles D, Prendeville W, Patnick J.
British J Obstet Gynaecol 2015; doi: 10.1111/1471-0528.13839.
46Cervical Cerclage for Preterm Birth Prevention in Twin Gestations with Short Cervix: A Case-Control_ Study.
Houlihan C, Poon LC, Ciarlo M, Kim E, Guzman ER, Nicolaides KH.
Ultrasound Obstet Gynecol 2016, doi: 10.1002/uog.15918.
47Cervical pessary for prevention of preterm birth in singleton pregnancies with short cervical length: a multicentre, randomized controlled trial.
Nicolaides KH, Syngelaki A, Poon LC, Picciarelli G, Tul N, Zamprakou A, Skyfta E, Parra-Cordero M, Palma-Dias R, Rodriquez Calvo J.
New England Journal of Medicine 2016; 374:1044-52.
48Contingent Screening for Small by Weight for Gestational Age Neonates.
Frick AP, Nicolaides KH, Poon LC.
Pediatr Endocrinol Rev 2016;13:568-573.
49The use of ultrasound and other markers for early detection of preeclampsia.
O'Gorman N, Nicolaides KH, Poon LC.
Womens Health (Lond Engl) 2016;12:199-207.
50Clinical implementation of routine screening for fetal trisomies by the cell-free DNA test contingent on results from first-trimester combined test.
Gil MM, Revello R, Poon LC, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016; 47:45-52.
51Prediction of large for gestational age neonates: Screening by maternal factors and biomarkers in the three trimesters of pregnancy.
Frick A, Syngelaki S, Zheng MM, Poon LC*, Nicolaides KH.
Ultrasound in Obstet Gynecol 2016;47:332-339.
52Current controversies in prenatal diagnosis 3: Is there still a Value in a Nuchal Translucency Screening Ultrasound in conjunction with Maternal Plasma Non-Invasive cell free DNA testing?’
Wilson RD, Poon LC, and Ghidini A.
Prenatal Diagnosis 2015; doi: 10.1002/pd.4719. [Epub ahead of print_]
53First trimester prediction of HELLP Syndrome.
Oliveira N, Poon LC, Nicolaides KH, Baschat AA.
Prenatal diagnosis 2016; 36:29-33.
54Clinical validation of the IONA® test for first-trimester detection of trisomy 21, 18 and 13.
Poon LC, Dumidrascu-Diris D, Francisco C, Fantasia I, Nicolaides KH.
Ultrasound Obstet Gynecol 2016; 47:184-187
55Cervical pessaries for prevention of preterm birth: a randomised controlled trial.
Nicolaides KH, Syngelaki A, Poon LC, De Paco C, Plasencia W, Molina F, Picciarelli G, Tul N, Celik E, Lau TK, Conturso R.
Am J Obstet Gynecol 2016, 214:3.e1-9
56The prediction of preterm birth in twin pregnancy: an individual patient level meta-analysis.
Kindinger LM, Poon LC, Cacciatore S, MacIntyre, Fox NS, Schuit E, Mol B, Liem S, Lim A, Hermans F, Serra V, Perales A, Darzi A, Bennett P, Nicolaides KH, Teoh TG.
British J Obstet Gynaecol 2016; 123:877-884.
57Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation.
O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2015, pii: S0002-9378(15)00900-X. doi: 10.1016/j.ajog.2015.08.034. [Epub ahead of print_]
58Prediction of small for gestational age neonates: screening by biophysical and biochemical markers at 19-24 weeks.
Poon LC, Lesmes C, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol. 2015 May 18. doi: 10.1002/uog.14904. [Epub ahead of print_]
59Poon L. Re: Prediction of early- and late-onset pregnancy-induced hypertension using placental volume on three-dimensional ultrasound and uterine artery Doppler.
T. Arakaki, J. Hasegawa, M. Nakamura, S. Hamada, M. Muramoto, H. Takita, K. Ichizuka and A. Sekizawa. Ultrasound Obstet Gynecol 2015; 45: 539-543.
Ultrasound Obstet Gynecol 2015;45:513.
60Prediction of small for gestational age neonates: Screening by maternal serum biochemical markers at 19-24 weeks.
Lesmes C, Gallo DM, Gonzalez R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol. 2015 May 13. doi: 10.1002/uog.14899. [Epub ahead of print_]
61Prediction of small-for-gestational-age neonates: maternal biochemical markers at 30-34 weeks.
Bakalis S, Gallo DM, Mendez O, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 46: 208-215.
62Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks.
Bakalis S, Peeva G, Gonzalez R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol. 2015 Mar 31. doi: 10.1002/uog.14863. [Epub ahead of print_]
63Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.
Fadigas C, Peeva G, Mendez O, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 46: 191-197.
64Prediction of small for gestational age neonates: screening by uterine artery Doppler and mean arterial pressure at 19-24 weeks.
Lesmes C, Gallo DM, Saiid Y, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol. 2015 Mar 24. doi: 10.1002/uog.14855. [Epub ahead of print_]
65Prediction of small-for-gestational-age neonates: screening by uterine artery Doppler and mean arterial pressure at 35-37 weeks.
Fadigas C, Guerra L, Garcia-Tizon Larroca S, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 715-721.
66Umbilical and fetal middle cerebral artery Doppler at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Akolekar R, Syngelaki A, Gallo DM, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 46: 82-92.
67Prediction of small-for-gestational-age neonates: screening by fetal biometry at 35-37 weeks.
Fadigas C, Saiid Y, Gonzalez R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 559-565.
68Competing risks model in screening for preeclampsia by maternal characteristics and medical history.
Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2015; 213: 62.e1-62.e10.
69Prediction of small for gestational age neonates: screening by fetal biometry at 19-24 weeks.
Lesmes C, Gallo D, Panaiotova J, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 46: 198-207.
70Umbilical and fetal middle cerebral artery Doppler at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Bakalis S, Akolekar R, Gallo DM, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 409-420.
71Prediction of small for gestational age neonates: Screening by uterine artery Doppler and mean arterial pressure at 30-34 weeks.
Bakalis S, Stoilov B, Akolekar R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 707-714.
72Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Wright A, Wright D, Ispas CA, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 698-706.
73Prediction of small for gestational age neonates: screening by fetal biometry at 30-34 weeks.
Bakalis S, Silva M, Akolekar R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 551-558.
74UK NHS pilot study on cell-free DNA testing in screening for fetal trisomies: Factors affecting uptake.
Gil MM, Giunta G, Macalli EA, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 67-73.
75Fetal fraction in maternal plasma cell-free DNA in the prediction of spontaneous preterm delivery.
Quezada MS, Francisco C, Dumitrascu-Biris D, Nicolaides KH, Poon LC*.
Ultrasound Obstet Gynecol 2015; 45: 101-105.
76Maternal plasma cell-free DNA in the prediction of preeclampsia.
Rolnik DL, O’Gorman N, Fiolna M, van den Boom D, Nicolaides KH, Poon LC*.
Ultrasound Obstet Gynecol 2015; 45: 106-111.
77Early prediction of preeclampsia.
Poon LC, Nicolaides KH.
Obstet Gynecol Int. 2014; 2014: 297397.
78Management of hypertriglyceridaemia-induced acute pancreatitis in pregnancy.
Amin T, Poon L, Teoh T, Moorthy K, Robinson S.
J Matern Fetal Neonatal Med. 2014 Jul 29:1-13. [Epub ahead of print_]
79Maternal serum anti-Müllerian hormone at 11-13 weeks' gestation in the prediction of preeclampsia.
Birdir C, Fryze J, Vasiliadis H, Nicolaides KH, Poon LC*.
J Matern Fetal Neonatal Med 2015; 28: 954-958.
80Competing risk model in screening for preeclampsia by mean arterial pressure and uterine artery pulsatility index at 30-33 weeks' gestation.
Tayyar A, Garcia-Tizon Larroca S, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther. 2014; 36: 18-27.
81Demographic factors that can be used to predict early-onset pre-eclampsia.
Leung C, Saaid R, Pedersen L, Park F, Poon L, Hyett J.
J Matern Fetal Neonatal Med 2015; 28: 535-539.
82First-trimester maternal factors and biomarker screening for preeclampsia.
Poon LC, Nicolaides KH.
Prenat Diagn 2014; 34: 618-627.
83Successful induction of labor: prediction by pre-induction cervical length, angle of progression and cervical elastography.
Pereira S, Frick AP, Poon LC, Zamprakou A, Nicolaides KH.
Ultrasound Obstet Gynecol 2014; 44: 468-475.
84Is High Fetal Nuchal Translucency Associated with Submicroscopic Chromosomal Abnormalities by Array CGH?
Huang J, Poon LC, Akolekar R, Choy KW, Leung TY, Nicolaides KH.
Ultrasound Obstet Gynecol 2014; 43: 620-624.
85Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks’ gestation.
Garcia-Tizon Larroca S, Tayyar A, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014; 36: 9-17.
86Prediction of preeclampsia by mean arterial pressure at 11-13 and 20-24 weeks’ gestation.
Gallo D, Poon LC, Fernandez M, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014; 36: 28-37.
87Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks’ gestation.
Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014; 35: 240-248.
88Optimal method and timing of intrauterine intervention in TRAP sequence: case study and meta-analysis.
Chaveeva P, Poon LC, Sotiriadis A, Kosinski P, Nicolaides KH.
Fetal Diagn Ther 2014; 35: 267-279.
89Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13, 20-24 and 30-34 weeks’ gestation in late onset preeclampsia and small for gestational age.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014; 35: 249-257.
90Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13 weeks’ gestation in preeclampsia and small for gestational age.
Fetal Diagn Therr 2014; 35: 249-257.
91Prediction of preeclampsia by uterine artery Doppler at 20-24 weeks’ gestation.
Gallo D, Poon LC, Akolekar R, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013; 1: 241-247.
92Trichorionic and dichorionic triplet pregnancies at 10-14 weeks: Outcome after embryo reduction compared to expectant management.
Chaveeva P, Kosinski P, Puglia D, Poon L, Nicolaides K.
Fetal Diagn Ther 2013; 1: 199-205.
93First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014; 35: 185-192.
94Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy.
Park FJ, Leung CH, Poon LC, Williams PF, Rothwell SJ, Hyett JA.
Aust N Z J Obstet Gynaecol 2013; 53: 532-539.
95How feasible is expectant management of interstitial ectopic pregnancy?
Poon LC, Emmanuel E, Ross J, Johns J.
Ultrasound Obstet Gynecol 2013, Ultrasound Obstet Gynecol 2014; 43: 317-321.
96Association of placental perfusion, as assessed by magnetic resonance imaging and uterine artery Doppler ultrasound, and its relationship to pregnancy outcome.
Derwig I, Lythgoe DJ, Barker GJ, Poon L, Gowland P, Yeung R, Fernando Z, Nicolaides, KH.
Placenta 2013; 34: 885-891.
97First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell free DNA testing.
Nicolaides KH, Wright D, Poon L, Syngelaki A, Gil M.
Ultrasound Obstet Gynecol 2013; 42: 41-50.
98Second-trimester screening for trisomy 21 using prefrontal space ratio.
Chaveeva P, Agathokleous M, Poon LC, Markova D, Nicolaides KH.
Fetal Diagn Ther 2013; 34: 50-55.
99Maternal thyroid function at 11-13 weeks’ gestation in twin pregnancy.
Ashoor G, Muto O, Poon LC, Abdulla M, Nicolaides KH.
Thyroid 2013; 23: 1165-1171.
100Maternal serum cytokines at 30-33 weeks in the prediction of preeclampsia.
Mosimann B, Wagner M, Poon LC, Bansal AS, Nicolaides KH.
Prenatal Diagnosis 2013; 33: 823-830.
101Association of placental T2 relaxation times and uterine artery Doppler ultrasound measures of placental blood flow.
Derwig I, Barker GJ, Poon L, Zelaya F, Gowland P, Lythgoe DJ, Nicolaides KH.
Placenta 2013; 34: 474-479.
102Natural killer cells and their activation status in normal pregnancy.
Mosimann B, Wagner M, Shehata H, Poon LC, Ford B, Nicolaides KH, Bansal AS.
International Journal of Reproductive Medicine 2013; 2013: 906813.
103Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks’ gestation: Relation to fetal and maternal characteristics and pregnancy outcomes.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 215-223.
104Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 164-172.
105Meta-analysis of second-trimester markers for trisomy 21.
Agathokleous M, Chaveeva P, Poon LC, Kosinski P, Nicolaides KH.
Ultrasound Obstet Gynecol 2013; 41: 247-261.
106Maternal serum tumour necrosis factor receptor 1 (TNF-R1) at 30-33 weeks in the prediction of preeclampsia.
Mosimann B, Wagner M, Birdir C, Poon LC, Nicolaides KH.
J Matern Fetal Neonatal Med 2013; 26: 763-767.
107Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics.
Ashoor G, Syngelaki A, Poon L, Rezende J, Nicolaides K.
Ultrasound Obstet Gynecol 2013; 41: 26-32.
108Maternal serum retinol-binding protein-4 at 11-13 weeks’ gestation in normal and pathological pregnancies.
Nanda S, Nikoletakis G, Markova D, Poon LC, Nicolaides KH.
Metabolism 2013; 62: 814-819.
109Maternal serum activin-A at 30-33 weeks in the prediction of preeclampsia.
Lai J, Pinas A, Syngelaki A, Poon LC, Nicolaides KH.
J Matern Fetal Neonatal Med 2013; 26: 733-737.
110Mean arterial pressure, systolic and diastolic blood pressure at 30–33 weeks in the prediction of preeclampsia.
Lai J, Poon LC, Bakalis S, Markova D, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 173-181.
111Uterine artery Doppler at 30–33 weeks’ gestation in the prediction of preeclampsia.
Lai J, Poon LC, Pinas A, Bakalis S, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 156-163.
112Second-trimester uterine artery Doppler in the prediction of stillbirths.
Poon LC, Volpe N, Muto B, Yu CKH, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 28-35.
113Combined screening for preeclampsia and small for gestational age at 11–13 weeks.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 16-27.
114Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 8-15.
115Maternal serum soluble endoglin (sEng) at 30-33 weeks in the prediction of preeclampsia.
Lai J, Syngelaki A, Poon LC, Nucci M, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 149-155.
116A competing risks model in early screening for preeclampsia.
Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH.
Fetal Diagn Ther 2012; 32: 171-178.
117Birthweight with gestation and maternal characteristics in live births and stillbirths.
Poon LC, Volpe N, Muto B, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2012; 32: 156-165.
118C-reactive protein at 11 to 13 weeks’ gestation in spontaneous early preterm delivery.
Bakalis S, Poon LC, Vayna AM, Pafilis I, Nicolaides KH.
J Matern Fetal Neonatal Med 2012; 25: 2475-2478.
119Maternal serum ferritin at 11 to 13 weeks’ gestation in spontaneous early preterm delivery.
Beta J, Poon LC, Bakalis S, Mosimann B, Nicolaides KH.
J Matern Fetal Neonatal Med 2012; 25:1852-1855.
120Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks’ gestation: Effect of maternal and fetal factors.
Ashoor G, Poon LC, Syngelaki A, Mosimann B, Nicolaides KH.
Fetal Diagn Ther 2012; 31: 237-243.
121First trimester screening for spontaneous preterm delivery with maternal characteristics and cervical length.
Greco E, Gupta R, Syngelaki A, Poon LC, Nicolaides KH.
Fetal Diagn Ther 2012; 31: 154-161.
122Protocol for measurement of mean arterial pressure at 11-13 weeks’ gestation.
Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2012; 31: 42-48.
123First trimester screening for neural tube defects using AFP.
Bredaki FE, Poon LC, Birdir C, Escalante D, Nicolaides KH.
Fetal Diagn Ther 2012; 31: 109-114.
124Maternal serum resistin at 11-13 weeks’ gestation in normal and pathological pregnancies.
Nanda S, Poon LC, Muhaisen M, Acosta IC, Nicolaides KH.
Metabolism 2012; 61: 699-705.
125Large loop excision of transformation zone and cervical length in the prediction of spontaneous preterm delivery.
Poon LC, Savvas M, Zamblera D, Skyfta E, Nicolaides KH.
BJOG 2012; 119: 692-698.
126Systolic diastolic and mean arterial pressure at 11-13 weeks in the prediction of hypertensive disorders in pregnancy: a prospective screening study.
Poon LC, Kametas NA, Valencia C, Chelemen T, Nicolaides KH.
Hypertens Pregnancy 2011; 30: 93-107.
127First-trimester prediction of macrosomia.
Poon LC, Karagiannis G, Stratieva V, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2011; 29: 139-147.
128Reference range of birth weight with gestation and first-trimester prediction of small for gestation neonates.
Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH.
Prenat Diagn 2011; 31: 58-65.
129Normal ranges of embryonic length, embryonic heart rate, gestational sac diameter and yolk sac diameter in early pregnancy.
Papaioannou GKI, Syngelaki A, Poon LC, Ross J, Nicolaides KH.
Fetal Diagn Ther 2010; 28: 207-219.
130Hypertensive disorders in pregnancy: Screening by biophysical and biochemical markers at 11-13 weeks.
Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2010; 35: 662-670.
131Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks.
Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH.
Prenat Diagn 2010; 30: 216-223.
132Hypertensive disorders in pregnancy: Screening by uterine artery Doppler and blood pressure at 11-13 weeks.
Poon LC, Karagiannis G, Leal A, Romero Infante X, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 34: 497-502.
133Hypertensive disorders in pregnancy: Screening by uterine artery Doppler at 11-13 weeks.
Poon LC, Staboulidou I, Maiz N, Plasencia W, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 34: 142-148.
134Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach.
Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH.
J Hum Hypertens 2010; 24: 104-110.
135First-trimester prediction of hypertensive disorders in pregnancy.
Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH.
Hypertension 2009; 53: 812-818.
136First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH.
Prenatal Diagnosis 2009; 29: 553-559.
137Maternal serum placental growth factor (plgf) at 11+0 to 13+6 weeks of gestation in small for gestational age pregnancy.
Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH.
Prenatal Diagnosis 2008; 28: 1110-1115.
138First trimester urinary placental growth factor and development of pre-eclampsia.
Savvidou M, Akolekar R, Zaragoza E, Poon L, Nicolaides KH.
BJOG 2009; 116: 643-647.
139First-trimester maternal serum tumor necrosis factor receptor-1 (TNF-R1) and preeclampsia.
Leal AM, Poon LC, Frisova V, Veduta A, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 33: 135-141.
140Maternal serum placental growth factor (plgf) at 11+0 to 13+6 weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2008; 32: 732-739.
141Maternal serum placental growth factor (plgf) at 11+0-13+6 weeks in chromosomally abnormal pregnancies.
Zaragoza E, Akolekar R, Poon LC, Pepes S, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 33: 382-386.
142First-trimester maternal serum PAPP-A and preeclampsia.
Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 33: 23-33.
143Maternal serum ADAM12 (A Disintegrin And Metalloprotease) in chromosomally abnormal pregnancies at 11+0-13+6 weeks.
Poon LC, Chelemen T, Minekawa R, Frisova V, Nicolaides KH.
American Journal Obstetrics and Gynecology 2009; 200: 508.e1-6.
144First trimester maternal serum A Disintegrin And Metalloprotease 12 and adverse pregnancy outcome.
Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH.
Obstetric Gynecol 2008; 112: 1082-1090.
145Fetal Medicine Foundation Prolonged Pregnancy Group. Cervical length and maternal factors in expectantly managed prolonged pregnancy: prediction of onset of labor and mode of delivery.
Rao A, Celik E, Poggi S, Poon L, Nicolaides KH;
Ultrasound Obstet Gynecol 2008; 32: 646-651.
146Prediction of preeclampsia by a combination of maternal history, uterine artery doppler and mean arterial pressure.
Onwudiwe N, Yu CKH, Poon LC, Spiliopoulos I, Nicolaides KH.
Ultrasound Obstet Gynecol 2008; 32: 877-883.
147Uterine artery Doppler at 11+0-13+6 weeks and 21+0-24+6 weeks in the prediction of pre-eclampsia.
Plasencia W, Maiz N, Poon L, Yu C, Nicolaides KH.
Ultrasound Obstet Gynecol 2008; 32: 138-146.
148Inter-arm blood pressure differences in pregnant women.
Poon LC, Kametas N, Strobl I, Pachoumi C, Nicolaides KH.
BJOG 2008; 115: 1122-1130.
149Mean arterial pressure at 11+0-13+6 weeks in the prediction of pre-eclampsia.
Poon LC, Kametas N, Pandeva IV, Valencia CM, Nicolaides KH.
Hypertension 2008; 51: 1027-1033.
150Urine albumin concentration and albumin-to-creatinine ratio at 11+0-13+6 weeks in the prediction of pre-eclampsia.
Poon LC, Kametas N, Bonino S, Vercellotti E, Nicolaides KH.
BJOG 2008; 115: 866-873.
151Blood pressure levels correlate with intra-individual variability using an automated device in early pregnancy.
Poon LC, Kametas N, Valencia CM, Pandeva IV, Nicolaides KH.
J Hum Hypertens 2008; 22: 438-440.
152Tetralogy of Fallot in the fetus in the current era.
Poon LC, Huggon I, Zidere V and Allan LD.
Ultrasound Obstet Gynecol 2007; 29: 625-627.
153Audit of the effectiveness of cervical preparation with Dilapan prior to late second trimester (20-24 weeks) surgical termination of pregnancy.
Poon LC, Parsons J.
BJOG 2007; 114: 485-488.